Af­ter ini­tial com­mer­cial for­ay, Chi­na's CStone mulls sale — re­port

CStone Phar­ma­ceu­ti­cals, the can­cer drug de­vel­op­er be­hind a PD-L1 drug li­censed by Pfiz­er in Chi­na and EQRx around the world, is re­port­ed­ly con­sid­er­ing a sale.

The sev­en-year-old Chi­nese biotech has en­gaged Gold­man Sachs to ex­plore strate­gic op­tions and seek out po­ten­tial buy­ers, Bloomberg re­port­ed, cit­ing peo­ple fa­mil­iar with the mat­ter. Cur­rent­ly list­ed on the Hong Kong Stock Ex­change, it’s al­so con­sid­er­ing a sale of a con­trol­ling stake.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER